European Journal of Cancer
Volume 46, Issue 1 , Pages 150-159 , January 2010

What determines individuals’ preferences for colorectal cancer screening programmes? A discrete choice experiment

  • L. van Dam

      Affiliations

    • Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Centre Rotterdam, Room Ba-393, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands
    • Corresponding Author InformationCorresponding author: Address: Department of Gastroenterology and Hepatology, Room Ba-393, Erasmus MC, University Medical Centre Rotterdam, s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands. Tel.: +31 (0)10 7032983; fax: +31 (0)10 7034682.
    • ,
  • L. Hol

      Affiliations

    • Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Centre Rotterdam, Room Ba-393, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands
    • ,
  • E.W. de Bekker-Grob

      Affiliations

    • Department of Public Health, Erasmus MC, University Medical Centre Rotterdam, The Netherlands
    • ,
  • E.W. Steyerberg

      Affiliations

    • Department of Public Health, Erasmus MC, University Medical Centre Rotterdam, The Netherlands
    • ,
  • E.J. Kuipers

      Affiliations

    • Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Centre Rotterdam, Room Ba-393, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands
    • Department of Internal Medicine, Erasmus MC, University Medical Centre Rotterdam, The Netherlands
    • ,
  • J.D.F. Habbema

      Affiliations

    • Department of Public Health, Erasmus MC, University Medical Centre Rotterdam, The Netherlands
    • ,
  • M.L. Essink-Bot

      Affiliations

    • Department of Social Medicine, Academic Medical Centre, Amsterdam, The Netherlands
    • Department of Public Health, Erasmus MC, University Medical Centre Rotterdam, The Netherlands
    • ,
  • M.E. van Leerdam

      Affiliations

    • Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Centre Rotterdam, Room Ba-393, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands

Received 8 April 2009 ,Revised 3 July 2009 ,Accepted 17 July 2009.

References 

  1. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18(3):581–592
  2. Karim-Kos HE, de VE, Soerjomataram I, et al. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer. 2008;44(10):1345–1389
  3. Faivre J, Dancourt V, Lejeune C, et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology. 2004;126(7):1674–1680
  4. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348(9040):1472–1477
  5. Hoff G, Grotmol T, Skovlund E, Bretthauer M. Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial. BMJ. 2009;338:b1846
  6. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348(9040):1467–1471
  7. Lindholm E, Brevinge H, Haglind E. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer. Brit J Surg. 2008;95(8):1029–1036
  8. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. New Engl J Med 1993;328(19):1365–71.
  9. Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst. 1999;91(5):434–437
  10. Scholefield JH, Moss S, Sufi F, Mangham CM, Hardcastle JD. Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial. Gut. 2002;50(6):840–844
  11. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. New Engl J Med 1993;329(27):1977–81.
  12. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin. 2008;58(3):130–160
  13. Hol L, van Leerdam ME, van Ballegooijen M, et al. Screening for colorectal cancer; randomised trial comparing guiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut [in press].
  14. Rebolj M, van BM, Berkers LM, Habbema D. Monitoring a national cancer prevention program: successful changes in cervical cancer screening in the Netherlands. Int J Cancer. 2007;120(4):806–812
  15. Schopper D, de WC. How effective are breast cancer screening programmes by mammography? Review of the current evidence. Eur J Cancer 2009;April 22.
  16. Manfredi S, Piette C, Durand G, et al. Colonoscopy results of a French regional FOBT-based colorectal cancer screening program with high compliance. Endoscopy. 2008;40(5):422–427
  17. van Rossum LG, van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology. 2008;135(1):82–90
  18. Vernon SW. Participation in colorectal cancer screening: a review. J Natl Cancer Inst. 1997;89(19):1406–1422
  19. Vogelaar I, van BM, Schrag D, et al. How much can current interventions reduce colorectal cancer mortality in the US? Mortality projections for scenarios of risk-factor modification, screening, and treatment. Cancer. 2006;107(7):1624–1633
  20. Blalock SJ, DeVellis BM, Afifi RA, Sandler RS. Risk perceptions and participation in colorectal cancer screening. Health Psychol. 1990;9(6):792–806
  21. Keighley MR, O’Morain C, Giacosa A, et al. Public awareness of risk factors and screening for colorectal cancer in Europe. Eur J Cancer Prev. 2004;13(4):257–262
  22. Phillips KA, Van BS, Marshall D, Walsh J, Thabane L. A review of studies examining stated preferences for cancer screening. Prev Chronic Dis. 2006;3(3):A75
  23. Louviere JJ, Hensher DA, Swait JD. Stated choice methods: analysis and applications. Cambridge, UK: Cambridge University Press; 2000;
  24. Caldon LJ, Walters SJ, Ratcliffe J, Reed MW. What influences clinicians’ operative preferences for women with breast cancer? An application of the discrete choice experiment. Eur J Cancer. 2007;43(11):1662–1669
  25. Johnson FR, Ozdemir S, Mansfield C, et al. Crohn’s disease patients’ risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology. 2007;133(3):769–779
  26. Ryan M. Discrete choice experiments in health care. BMJ. 2004;328(7436):360–361
  27. Sloane NJA. A library of orthogonal arrays; 2008. <http://www.research.att.com/njas/oadir/>.
  28. Street DJ, Burgess L, Louviere JJ. Quick and easy choice sets: constructing optimal and nearly optimal stated choice experiments. Int J Res Market. 2005;22:459–470
  29. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095–1108
  30. Lancsar E, Louviere J. Deleting ‘irrational’ responses from discrete choice experiments: a case of investigating or imposing preferences?. Health Econ. 2006;15(8):797–811
  31. Ryan M, Watson V, Entwistle V. Rationalising the ‘irrational’: a think aloud study of discrete choice experiment responses. Health Econ. 2009;18(3):321–336
  32. Gerard K, Shanahan M, Louviere J. Using discrete choice modelling to investigate breast screening participation. In:  Ryan M,  Gerard K,  Amaya-Amaya M editor. Using discrete choice experiments to value health and health care. Dordrecht: Springer; 2008;p. 117–137
  33. Hall J, Kenny P, King M, et al. Using stated preference discrete choice modelling to evaluate the introduction of varicella vaccination. Health Econ. 2002;11(5):457–465
  34. Hewitson P, Glasziou P, Watson E, Towler B, Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol. 2008;103(6):1541–1549
  35. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, et al. Evaluating test strategies for colorectal cancer screening: a decision analysis for the US. Preventive Services Task Force. Ann Intern Med 2008;149(9):659–69.
  36. Gyrd-Hansen D, Sogaard J. Analysing public preferences for cancer screening programmes. Health Econ. 2001;10(7):617–634
  37. Hawley ST, Volk RJ, Krishnamurthy P, et al. Preferences for colorectal cancer screening among racially/ethnically diverse primary care patients. Med Care 2008;46(9 Suppl 1):S10–16.
  38. Howard K, Salkeld G. Does attribute framing in discrete choice experiments influence willingness to pay? Results from a discrete choice experiment in screening for colorectal cancer. Value Health 2008;July 24.
  39. Marshall DA, Johnson FR, Phillips KA, et al. Measuring patient preferences for colorectal cancer screening using a choice-format survey. Value Health. 2007;10(5):415–430
  40. Marshall DA, Johnson FR, Kulin NA, et al. How do physician assessments of patient preferences for colorectal cancer screening tests differ from actual preferences? A comparison in Canada and the United States using a stated-choice survey. Health Econ 2009;February 3.
  41. Salkeld G, Solomon M, Short L, Ryan M, Ward JE. Evidence-based consumer choice: a case study in colorectal cancer screening. Aust NZ J Public Health. 2003;27(4):449–455
  42. Salkeld GP, Solomon MJ, Short L, Ward J. Measuring the importance of attributes that influence consumer attitudes to colorectal cancer screening. ANZ J Surg. 2003;73(3):128–132
  43. Holloway RM, Wilkinson C, Peters TJ, et al. Cluster-randomised trial of risk communication to enhance informed uptake of cervical screening. Brit J Gen Pract. 2003;53(493):620–625
  44. Cantor SB, Volk RJ, Cass AR, Gilani J, Spann SJ. Psychological benefits of prostate cancer screening: the role of reassurance. Health Expect. 2002;5(2):104–113
  45. Whynes DK, Philips Z, Avis M. Why do women participate in the English cervical cancer screening programme?. J Health Econ. 2007;26(2):306–325
  46. Salkeld G, Ryan M, Short L. The veil of experience: do consumers prefer what they know best?. Health Econ. 2000;9(3):267–270
  47. Codori AM, Petersen GM, Miglioretti DL, Boyd P. Health beliefs and endoscopic screening for colorectal cancer: potential for cancer prevention. Prev Med 2001;33(2 Pt 1):128–36.
  48. Janz NK, Lakhani I, Vijan S, et al. Determinants of colorectal cancer screening use, attempts, and non-use. Prev Med. 2007;44(5):452–458
  49. Marbet UA, Bauerfeind P, Brunner J, et al. Colonoscopy is the preferred colorectal cancer screening method in a population-based program. Endoscopy. 2008;40(8):650–655
  50. Edwards A, Elwyn G, Mulley A. Explaining risks: turning numerical data into meaningful pictures. BMJ. 2002;324(7341):827–830

PII: S0959-8049(09)00538-3

doi: 10.1016/j.ejca.2009.07.014

European Journal of Cancer
Volume 46, Issue 1 , Pages 150-159 , January 2010

Article Tools

* Image Usage & Resolution